drugset

drugset / Trial / NCT01018966

Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

NCT01018966 ↗

Phase 1 Completed 25 enrolled R-Pharm

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the DLT, MTD and recommended Phase II dose of ixabepilone in Japanese patients with solid tumors.

Timeline

Start: 2004-04
Primary completion: 2005-03
Completion: 2005-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ixabepilone	Small molecule	—	Intravenous

Indications